INVA (Innoviva) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 05, 2026)


INVA Innoviva Inc INVA
90 GF Score
Price $22.31
GF Value $20.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Innoviva Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Innoviva's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

INVA vs BCAX, ZYME, SRPT: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Innoviva's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innoviva Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Innoviva's Margin of Safety % (DCF Dividends Based) falls into.


INVA
90GF Score
Innoviva Inc INVA
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innoviva (INVA) Overvalued in 2026?

Based on GuruFocus' analysis, Innoviva stock appears to be overvalued. The current stock price of $22.31 is trading 9.3% above its estimated GF Value™ of $20.40. GuruFocus considers Innoviva to be Fairly Valued.

Key valuation signals for INVA:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $20.40 vs. price of $22.31 (9.3% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the INVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innoviva Business Description

Other Exchanges HVE:Germany
Address 1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
90GF Score

Get the complete analysis for INVA

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.31
Price
$20.40
GF Value